Cellectis S.A. (ALCLS.PA)
EUR 1.41
(-0.71%)
EUR 1.41
(-0.71%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 97.32 Million USD | -9.1% |
| 2022 | 107.06 Million USD | -13.03% |
| 2021 | 123.11 Million USD | 0.0% |
| 2020 | 123.11 Million USD | -3.33% |
| 2019 | 127.35 Million USD | 10.66% |
| 2018 | 115.08 Million USD | -0.12% |
| 2017 | 115.21 Million USD | 9.88% |
| 2016 | 104.85 Million USD | 26.54% |
| 2015 | 82.86 Million USD | 185.89% |
| 2014 | 28.98 Million USD | -56.82% |
| 2013 | 67.12 Million USD | 29.28% |
| 2012 | 51.92 Million USD | 21.38% |
| 2011 | 42.77 Million USD | 24.69% |
| 2010 | 34.3 Million USD | 24.7% |
| 2009 | 27.51 Million USD | 52.61% |
| 2008 | 18.02 Million USD | 73.23% |
| 2007 | 10.4 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 25.42 Million USD | -14.39% |
| 2024 Q2 | 25.27 Million USD | -0.59% |
| 2023 Q3 | 20.64 Million USD | -13.19% |
| 2023 FY | 97.32 Million USD | -9.1% |
| 2023 Q4 | 29.69 Million USD | 43.84% |
| 2023 Q1 | 23.23 Million USD | 10.68% |
| 2023 Q2 | 23.78 Million USD | 2.35% |
| 2022 Q4 | 20.99 Million USD | -36.4% |
| 2022 Q1 | 36.56 Million USD | 7.0% |
| 2022 FY | 107.06 Million USD | -13.03% |
| 2022 Q2 | 35.09 Million USD | -4.0% |
| 2022 Q3 | 33.01 Million USD | -5.94% |
| 2021 Q3 | 41.46 Million USD | 12.37% |
| 2021 Q2 | 36.9 Million USD | -1.23% |
| 2021 Q4 | 34.16 Million USD | -17.6% |
| 2021 FY | 123.11 Million USD | 0.0% |
| 2021 Q1 | 37.36 Million USD | 9.34% |
| 2020 FY | 123.11 Million USD | -3.33% |
| 2020 Q1 | 31.11 Million USD | -16.5% |
| 2020 Q2 | 30.1 Million USD | -3.25% |
| 2020 Q3 | 27.71 Million USD | -7.94% |
| 2020 Q4 | 34.16 Million USD | 23.28% |
| 2019 Q2 | 35.46 Million USD | 50.47% |
| 2019 Q3 | 30.88 Million USD | -12.92% |
| 2019 FY | 127.35 Million USD | 10.66% |
| 2019 Q1 | 23.56 Million USD | -20.15% |
| 2019 Q4 | 37.26 Million USD | 20.67% |
| 2018 FY | 115.08 Million USD | -0.12% |
| 2018 Q4 | 29.51 Million USD | 1.98% |
| 2018 Q3 | 28.93 Million USD | 10.52% |
| 2018 Q2 | 26.18 Million USD | -13.76% |
| 2018 Q1 | 30.36 Million USD | -6.88% |
| 2017 Q3 | 31.25 Million USD | 16.62% |
| 2017 Q4 | 32.6 Million USD | 4.32% |
| 2017 FY | 115.21 Million USD | 9.88% |
| 2017 Q2 | 26.8 Million USD | 3.22% |
| 2017 Q1 | 25.96 Million USD | -4.54% |
| 2016 Q2 | 28.42 Million USD | -6.96% |
| 2016 Q4 | 27.2 Million USD | 13.65% |
| 2016 Q3 | 23.93 Million USD | -15.79% |
| 2016 FY | 104.85 Million USD | 26.54% |
| 2016 Q1 | 30.54 Million USD | 14.22% |
| 2015 Q2 | 21.38 Million USD | 70.81% |
| 2015 FY | 82.86 Million USD | 185.89% |
| 2015 Q1 | 12.51 Million USD | 162.87% |
| 2015 Q4 | 26.74 Million USD | 14.76% |
| 2015 Q3 | 23.3 Million USD | 9.0% |
| 2014 Q1 | 9.54 Million USD | -27.3% |
| 2014 FY | 28.98 Million USD | -56.82% |
| 2014 Q4 | 4.76 Million USD | -4.09% |
| 2014 Q3 | 4.96 Million USD | -47.65% |
| 2014 Q2 | 9.48 Million USD | -0.64% |
| 2013 Q3 | 12.9 Million USD | -0.61% |
| 2013 Q4 | 13.12 Million USD | 1.75% |
| 2013 FY | 67.12 Million USD | 29.28% |
| 2013 Q1 | 12.79 Million USD | 84.86% |
| 2013 Q2 | 12.98 Million USD | 1.46% |
| 2012 Q4 | 6.92 Million USD | -47.02% |
| 2012 FY | 51.92 Million USD | 21.38% |
| 2012 Q3 | 13.06 Million USD | 0.0% |
| 2011 FY | 42.77 Million USD | 24.69% |
| 2010 FY | 34.3 Million USD | 24.7% |
| 2009 FY | 27.51 Million USD | 52.61% |
| 2008 FY | 18.02 Million USD | 73.23% |
| 2007 FY | 10.4 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -2229.902% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 23.596% |
| Adocia SA | 15.62 Million EUR | -522.689% |
| Aelis Farma SA | 18.81 Million EUR | -417.137% |
| Biophytis S.A. | 14.33 Million EUR | -578.993% |
| Advicenne S.A. | 8.21 Million EUR | -1084.662% |
| genOway Société anonyme | 16.73 Million EUR | -481.422% |
| IntegraGen SA | 5.35 Million EUR | -1718.212% |
| Medesis Pharma S.A. | 1.56 Million EUR | -6120.231% |
| Neovacs S.A. | 10.34 Million EUR | -840.877% |
| NFL Biosciences SA | 4.37 Million EUR | -2124.786% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -3419.902% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -5564.842% |
| Sensorion SA | 27.05 Million EUR | -259.729% |
| Theranexus Société Anonyme | 3 Million EUR | -3138.616% |
| TME Pharma N.V. | 5.49 Million EUR | -1670.42% |
| Valbiotis SA | 9.86 Million EUR | -886.118% |
| TheraVet SA | 1.64 Million EUR | -5818.581% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | -378.937% |
| DBV Technologies S.A. | 89.4 Million EUR | -8.852% |
| Genfit S.A. | 54.8 Million EUR | -77.578% |
| GeNeuro SA | 14.35 Million EUR | -577.843% |
| Innate Pharma S.A. | 64.57 Million EUR | -50.72% |
| Inventiva S.A. | 120.18 Million EUR | 19.026% |
| MaaT Pharma SA | 21.59 Million EUR | -350.597% |
| MedinCell S.A. | 32.92 Million EUR | -195.608% |
| Nanobiotix S.A. | 58.92 Million EUR | -65.153% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | -312.565% |
| Poxel S.A. | 28.76 Million EUR | -238.328% |
| GenSight Biologics S.A. | 32.66 Million EUR | -197.979% |
| Transgene SA | 31.23 Million EUR | -211.613% |
| Valneva SE | 134.92 Million EUR | 27.871% |